Click to search

Pharmacokinetics of cannabidiol administered by 3 delivery methods at 2 different dosages to healthy dogs.

Randomized controlled trial
Bartner LR, et al. Can J Vet Res. 2018.

Abstract

The purpose of this study was to determine the pharmacokinetics of cannabidiol (CBD) in healthy dogs. Thirty, healthy research dogs were assigned to receive 1 of 3 formulations (oral microencapsulated oil beads, oral CBD-infused oil, or CBD-infused transdermal cream), at a dose of 75 mg or 150 mg q12h for 6 wk. Serial cannabidiol plasma concentrations were measured over the first 12 h and repeated at 2, 4, and 6 wk. Higher systemic exposures were observed with the oral CBD-infused oil formulation and the half-life after a 75-mg and 150-mg dose was 199.7 ± 55.9 and 127.5 ± 32.2 min, respectively. Exposure is dose-proportional and the oral CBD-infused oil provides the most favorable pharmacokinetic profile.

PMID

30026641 [Indexed for MEDLINE]

PMCID

PMC6038832

Full text

 Citation 2 of 5 Back to results